Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor

Journal of Investigative Dermatology

Volumn 134, Issue 4, 2014, Pages 1143-1145

  Two, Aimee M ^a   Hata, Tissa R ^a   Nakatsuji, Teruaki ^a   Coda, Alvin B ^a   Kotol, Paul F ^a   Wu, Wiggin ^a   Shafiq, Faiza ^a   Huang, Eugene Y ^a,b,c   Gallo, Richard L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Therapeutics Clinical Research   (United States)

^c Skin EpiBiotics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; CARCINOEMBRYONIC ANTIGEN; CATHELICIDIN; DOXYCYCLINE; IMMUNOGLOBULIN A; KALLIKREIN 5; PLACEBO; SERINE PROTEINASE; TISSUE KALLIKREIN;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; FEMALE; HEMOSTASIS; HUMAN; IN VITRO STUDY; LETTER; MALE; MIDDLE AGED; PAPULOPUSTULAR ROSACEA; PILOT STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; ROSACEA; STRATUM CORNEUM; TREATMENT DURATION; VERY ELDERLY;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOCAPROIC ACID; ANTIMICROBIAL CATIONIC PEPTIDES; APROTININ; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; KALLIKREINS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PILOT PROJECTS; ROSACEA; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; SKIN; TREATMENT OUTCOME; TRYPSIN;

EID: 84897076005     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.472     Document Type: Letter

References (8)

1. Coda AB, Hata T, Miller J et al. (2013) Cathelici-din, KLK5 and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 69:570-7
2. Huang E, DiNardo A, Gallo R et al. (2013) Surface cathelicidin expression is a predictor of treatment success in papulopustular rosacea. J Invest Dermatol 133:S23
3. Kanada KN, Nakatsuji T, Gallo RL (2012) Doxycy-cline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol 132:1435-42
4. Koczulla R, von Degenfeld G, Kupatt C et al. (2003) An angiogenic role for the human peptide antiobitic LL-37/hCAP-18. J Clin Invest 111: 1165-72
5. Lande R, Gregorio J, Facchinetti V et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564-9
6. Morizane S, Yamasaki K, Muhleisen B et al. (2012) Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol 132: 135-43
7. Yamasaki K, Di Nardo A, Bardan A et al. (2007) Increased serine protease activity and cathe-licidin promotes skin inflammation in rosa-cea. Nat Med 13:975-80
8. Yamasaki K, Schauber J, Coda A et al. (2006) Kallikrein mediated proteolosis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 20:2068-80